Figure 3: Number of first approvals of monoclonal antibody against cancer and non-cancer disorders. Adapted from: Kaplon H, Reichert JM: Antibodies to watch in 2021. mAbs, 2022; 13: 1860476[7].
![Figure 3: Number of first approvals of monoclonal antibody against cancer and non-cancer disorders. Adapted from: Kaplon H, Reichert JM: Antibodies to watch in 2021<i>. mAbs,</i> 2022; 13: 1860476<sup>[7]</sup>.](articles/2022/36/4/images/TaiwanJPsychiatry_2022_36_4_148_365329_f3.jpg)
| Close | |
|
|
|
|
Figure 3: Number of first approvals of monoclonal antibody against cancer and non-cancer disorders. Adapted from: Kaplon H, Reichert JM: Antibodies to watch in 2021. mAbs, 2022; 13: 1860476[7].
|
|